Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma 5Central Nervous System Neoplasms 5Neuroblastoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Opsoclonus-Myoclonus Syndrome 2Meningeal Carcinomatosis 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Burkitt Lymphoma 2beta-Thalassemia 1Wilms Tumor 1Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Testicular Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neurotoxicity Syndromes 1Neurofibromatosis 1 1Neoplasms 1Neoplasm, Residual 1

Interventions

sodium thiosulfate 3Filgrastim 3Carboplatin 3etoposide phosphate 2Cyclophosphamide 2pegfilgrastim 1Vincristine 1Trastuzumab 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Mannitol 1Lomustine 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Genetic Therapy 1Etoposide 1Cytarabine 1Cefixime 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Rituximab × CNS × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡